References
- Bondesen S, Rasmussen S N, Rask-Madsen J. 5-Aminosalicylic acid in the treatment of inflammatory bowel disease. Acta Med Scand 1987; 221: 227–242
- Dew M J, Ebden P, Kidwal N S, Lee G, Evans B K, Rhodes J. Comparison of the absorption and metabolism of sulphasalazine and acrylic-coated 5-aminosalicylic acid in normal subjects and patients with colitis. Br J Clin Pharmacol 1984; 17: 474–476
- Myers B, Evans D NW, Rhodes J. Metabolism and urinary excretion of 5-aminosalicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract. Gut 1987; 28: 196–200
- Klotz U, Maier K E, Fisher C, Bauer K H. A new slow-release form of 5-aminosalicylic acid for the oral treatment of inflammatory bowel disease. Arz-neimittelforsch 1985; 35: 636–639
- Rasmussen S N, Bondesen S, Hvidberg E F. 5-Aminosalicylic acid in a slow-release preparation: bioavailability plasma level and excretion in humans. Gastroenterology 1982; 83: 1062–1070
- Rasmussen S N, Binder V, Maier K. Treatment of Crohn's disease with peroral 5-aminosalicylic acid. Gastroenterology 1983; 85: 1350–1353
- Rijk M CM, Van Schaik A, Van Tongeren J HM. Disposition of 5-aminosalicylic acid by 5-aminosalicylic acid delivering compounds. Scand I Gastroenterol 1988; 23: 107–112
- Järnerot G. Newer 5-aminosalicylic acid based drugs in chronic inflammatory bowel disease. Drugs 1989; 37: 73–86
- Christensen L A, Slot O, Sanchez G. Release of 5-aminosalicylic acid from Pentasa during normal and accelerated intestinal transit time. Br J Clin Pharmacol 1987; 23: 365–369
- Van Hees P AM, Bakker J H, Van Tongeren J HM. Effect of sulphapyridine, 5-aminosalicylic acid, and placebo in patients with idiopathic proctitis: a study to determine the active therapeutic moiety of sulphasalazine. Gut 1980; 21: 632–635
- Haagen Nielsen O, Bondesen S. Kinetics of 5-aminosalicylic acid after jejunal instillation in man. Br J Clin Pharmacol 1983; 16: 738–740
- Lee E JD, Ang S B. Simple and sensitive high-performance liquid chromatograph assay for 5-amino-salicylic acid and acetyl-5-aminosalicylic acid in serum. J Chromatogr 1987; 43: 300–304
- Hardy J G, Healy J NC, Lee S W, Reynolds J R. Gastrointestinal transit of an enteric-coated de-layed-release 5-aminosalicylic acid tablet. Aliment Pharmacol Ther 1987; 1: 209–216
- Terpstra I J, Bavelaar J F, Klooster N TM, Gro-Enendaal J W, Hespe W. In vitro dissolution of 5-aminosalicylic acid delivering compounds [Abstract 859]. Gastroenterol Int 1988; l, suppl 1
- Stolk L ML, Rietbroek R, Wiltink E, Mulder C JJ, Tytgat GN J, Tukker J J. In vitro dissolution of mesa-lazine compounds [Abstract]. Pharm Weekbl [Sci] 1989; 11: E11
- Ryan J R, Chremos A N, Vargas R, Mantell G, Johnson C L, McMahon F G. The effect of various dose regimens of famotidine on basal nocturnal and meal-stimulated gastric secretion. Clin Pharmacol Ther 1987; 42: 225–231
- Fallingborg J, Christensen L A, Ingeman-Nielsen M. Regional pH and transit times in the gut [Abstract]. Scand J Gastroenterol 1989; 24: 134, suppl 158
- Evans D F, Pye G, Branley R, Clark A G, Dyson T J, Hardcastle J D. Measurements of gastrointestinal pH profiles in normal ambulant human subjects. Gut 1988; 29: 1035–1041